Puma BiotechnologyCOVID-19 UPDATE

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to

Home About Us Pipeline News Investors Contacts Careers

Final efficacy results of neratinib in HER2-positive hormone receptor-positive early stage breast cancer from the Phase III ExteNET trial have been published in Clinical Breast Cancer. The full manuscript is available below:A Phase II trial evaluating diarrhea management strategies for NERLYNX® tablets, including dose escalation, has been published in the Annals of Oncology. The full manuscript is available below:
Corporate Fact Sheet

RECENT NEWSEVENTSCLINICAL TRIALS


Jan. 12, 2022 - Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
Read

Jan. 10, 2022 - Puma Biotechnology Releases Updated Corporate Presentation
Read

Jan. 4, 2022 - Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference
Read

Dec. 10, 2021 - Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
Read | Slides

Nov. 23, 2021 - Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
Read

Nov. 20, 2021 - Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting
Read

Nov. 19, 2021 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Read

Nov. 4, 2021 - Puma Biotechnology Reports Third Quarter 2021 Financial Results
Read

Oct. 21, 2021 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

Sept. 21, 2021 - Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference
Read

Sept. 7, 2021 - Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Read

Upcoming Events

- N/A -

Past Events

Jan. 10, 2022 - Puma Biotechnology Releases Updated Corporate Presentation
More

Jan. 10, 2022 - H.C. Wainwright BioConnect Conference
More

Dec. 7-10, 2021 - San Antonio Breast Cancer Symposium
More

Nov. 20, 2021 - Society for Neuro-Oncology Annual Meeting
More

Oct. 21, 2021 - Puma Biotechnology 3Q-2021 Financial Results Conference Call
More

Sept. 28, 2021 - Cantor Virtual Global Healthcare Conference
More

Sept. 13-15, 2021 - H.C. Wainwright 23rd Annual Global Investment Conference
More

 Puma-Sponsored Trials
Investigator-Sponsored Trials



Annual Report

2020 Annual Report


 Annual Report Archives

Contact

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com

Business Development:
info@pumabiotechnology.com

Investor Relations:
ir@pumabiotechnology.com

Follow Us:




© 2022 Puma Biotechnology, Inc. | Privacy Policy | Legal Notice | Site Map